We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
For an investigational study, proper monitoring was not ensured, IRB review and approval were not ensured, reviewing IRBs were not promptly informed of significant new information about an investigation, and FDA was not promptly informed of significant new information about an investigation.